

#### Influence of Donor Demographics on Graft Survival following Osteochondral Allograft Transplantation

Mario Hevesi MD PhD, Kyle R. Wagner BS, Ryan A. Quigley MD, Zachary D. Meeker BS, Nate Cohen, Landon P. Frazier BS, Joshua T. Kaiser BS, Adam B. Yanke MD PhD, Brian J. Cole MD MBA.



#### **Disclosures:**



Kyle R. Wagner BS; Ryan A. Quigley, MD; Zachary D. Meeker, BS; Landon P. Frazier, BS; Joshua T Kaiser, BS; Nate Cohen, BS: Nothing to disclose

Mario Hevesi, MD, PhD has received consulting fees from Envois, Moximed, and Vericel; and publishing royalties from Elsevier.

Adam B. Yanke, MD, PhD has received consulting fees from AlloSource, Arthrex Inc, Conmed Linvatec, JRF Ortho and Olympus; research support from Organogenesis and Vericel; holds stock or stock options in Patient IQ; and is an unpaid consultant for Smith and Nephew and Sparta Biomedical.

**Brian J. Cole, MD, MBA** has received grants from Aesculap, Regentis, and Arthrex; royalties from Arthrex and Elsevier; consulting fees from Acumed, Aesculap Biologics, Arthrex, Eendo Pharmaceuticals, Terumo BCT, and Lifenet; support for education from Endo Pharmaceuticals; hospitality payments from GE healthcare; honoraria from Vericel; speaking fees from Pacira Pharmaceuticals and Terumo BCT, and nonfinancial material support from Athletico, Encore Medical, JRF Ortho, Merck Sharp & Dohme, Samumed, and SportsTek Medical; he owns stock in Ossio, Regentis, and Bandgrip.

## **The Problem**

 Articular cartilage defects can be seen in up to 60% of knee arthroscopies

- Osteochondral allograft transplantation
  - MCID for IKDC: 75%
  - Survival: 86% and 82% at 5 and 10-years
- Cartilage restoration **increasingly performed** as access to fresh allografts improves

AJSM, 2021

Osteochondral Allograft Transplant for Focal Cartilage Defects of the Femoral Condyles: Clinically Significant Outcomes, Failures, and Survival at a Minimum 5-Year Follow-up

Ron Gilat <sup>1</sup> <sup>2</sup>, Eric D Haunschild <sup>1</sup>, Hailey P Huddleston <sup>1</sup>, Tracy M Tauro <sup>1</sup>, Sumit Patel <sup>3</sup>, Theodore S Wolfson <sup>1</sup>, Kevin C Parvaresh <sup>1</sup>, Adam B Yanke <sup>1</sup>, Brian J Cole <sup>1</sup>

J Knee Surg, 2020

Trends in the Surgical Treatment of Articular Cartilage Lesions in the United States from 2007 to 2016

Steven F DeFroda <sup>1</sup>, Steven L Bokshan <sup>1</sup>, Daniel S Yang <sup>1</sup>, Alan H Daniels <sup>1</sup>, Brett D Owens <sup>1</sup>



## **The Problem**



#### Do donor variables influence recipient outcomes?

#### AJSM, 2022

Association of Sex Mismatch Between Donor and Recipient With Graft Survivorship at 5 Years After Osteochondral Allograft Transplantation

Gergo Merkely <sup>1</sup>, Evan M Farina <sup>1</sup>, Chilan B G Leite <sup>1</sup> <sup>2</sup>, Jakob Ackermann <sup>3</sup>, Simon Görtz <sup>1</sup>, Christian Lattermann <sup>1</sup>, Andreas H Gomoll <sup>4</sup>

AJSM, 2020

#### Shorter Storage Time Is Strongly Associated With Improved Graft Survivorship at 5 Years After Osteochondral Allograft Transplantation

Gergo Merkely <sup>1</sup>, Jakob Ackermann <sup>2</sup>, Evan M Farina <sup>1</sup>, Courtney VanArsdale <sup>1</sup>, Christian Lattermann <sup>1</sup>, Andreas H Gomoll <sup>3</sup>

J Knee Surg, 2017

Patient Factors, Donor Age, and Graft Storage Duration Affect Osteochondral Allograft Outcomes in Knees with or without Comorbidities

Clayton W Nuelle <sup>1</sup>, Julia A V Nuelle <sup>1</sup>, James L Cook <sup>1</sup>, James P Stannard <sup>1</sup>

JBJS, 1989

The fate of articular cartilage after transplantation of fresh and cryopreserved tissue-antigen-matched and mismatched osteochondral allografts in dogs

S Stevenson <sup>1</sup>, G A Dannucci, N A Sharkey, R R Pool



#### **Purpose**

To evaluate whether donor sex and age, donor-recipient sex mismatch, and duration of graft storage affect clinical outcomes and failure rates following knee osteochondral allograft transplantation.

#### Influence of Donor Demographics on Graft Survival following Osteochondral Allograft Transplantation | AANA 2023 6

#### Methods

- Prospectively collected, single-surgeon database from 2003-2018
- Inclusion Criteria: primary OCA, minimum 2-year followup, data on allograft donor sex, age, and date of allograft expiration
- Exclusion Criteria: <2-years follow-up or revision OCA
- Failure = revision cartilage procedure or conversion to UKA or TKA







- **N = 459** primary OCAs performed
  - Included: N = 360
  - > Age: 31.2 ± 9.8 years
  - ➤ BMI: 26.6 ± 4.4 kg/m2
- Mean f/u 5.5 ± 2.6 years
  Range: 2.0-16.3
- Donor-recipient mismatch present in N = 149 (41%)
  - > More female recipients
  - > 79% of donors were male
  - ➤ Smaller defect size

Demographics and Intraoperative Variables					
Characteristic	Non-mismatch, N = 211	Mismatch, N = 149	P-value		
Sex			<0.001		
Female	58 (27%)	134 (90%)			
Male	153 (73%)	15 (10%)			
Age (years)	31.0 ± 9.7	31.6 ± 10.0	0.568		
BMI					
Male	27.9 ± 4.4	27.8 ± 4.3	0.714		
Female	25.7 ± 4.1	24.8 ± 3.8	0.149		
Laterality (right)	124 (59%)	82 (55%)	0.481		
Smoking status			0.861		
Current	14 (6.6%)	12 (8.1%)			
Former	8 (3.8%)	5 (3.4%)			
Never	189 (90%)	132 (89%)			
<b>Prior surgeries</b>	2.62 ± 1.56	2.69 ± 1.40	0.373		
WC	29 (14%)	17 (11%)	0.513		
Defect size (mm)	19.8 ± 4.3	18.2 ± 3.7	0.002		
Defect location					
MFC	112 (53%)	73 (49%)	0.445		
LFC	91 (43%)	62 (42%)	0.816		
Trochlea	25 (12%)	13 (8.7%)	0.342		
Patella	23 (11%)	24 (16%)	0.149		
Categorical variables listed as n (%); continuous variables listed as mean					
(SD). BMI, body mass index; LFC, lateral femoral condyle; MFC, medial					
femoral condyle; WC, worker's compensation status.					



- Isolated OCA in 45% cases
- Graft storage time: 24.3 ± 2.8 days
  Range: 14 28 days
- **Donor age:**  $22.9 \pm 6.2$  years
  - Younger donor age in those who received a sexmismatched allograft

Demographics and Intraoperative Variables					
Characteristic	Non-mismatch, N = 211	Mismatch, N = 149	P-value		
Major concomitant	119 (56%)	80 (54%)	0.611		
ACI	0 (0%)	2 (1.3%)	0.171		
MFX	16 (7.6%)	9 (6.0%)	0.571		
ACLR	14 (6.6%)	5 (3.4%)	0.170		
DFO	11 (5.2%)	5 (3.4%)	0.400		
НТО	21 (10.0%)	8 (5.4%)	0.116		
LMAT	54 (26%)	37 (25%)	0.870		
MMAT	40 (19%)	19 (13%)	0.117		
BMAC	20 (9.5%)	22 (15%)	0.124		
PRP	4 (1.9%)	3 (2.0%)	>0.999		
Donor age	23.6 ± 6.3	22.0 ± 5.9	0.023		
Days in storage	24.3 ± 2.8	24.1 ± 2.8	0.467		
Major concomitant procedure is defined as any of the listed procedures,					
apart from bone marrow aspirate concentrate (BMAC) or platelet-rich					
plasma (PRP). ACI, autologous chondrocyte implantation; ACLR, anterior					
cruciate ligament reconstruction; DFO, distal femoral osteotomy; HTO,					
high tibial osteotomy; LMAT, lateral meniscal transplantation; MFX,					
marrow stimulation; MMAT, medial meniscal transplantation.					



P > 0.05

## No donor variables predicted CSOs for subjective IKDC as well as KOOS subscales

Clinically Significant Outcomes for IKDC Subjective Form						
Variables included in model	Univariable P-value	Multivariable P-value	Odds Ratio			
MCID						
Days in storage (linear)	0.645	0.768	1.026 (0.867 - 1.230)			
Donor Age	0.112	0.061	0.922 (0.845 - 1.002)			
Donor Sex (female)	0.468	0.905	1.085 (0.292 - 4.634)			
Donor-Recipient Sex Mismatch	0.289	0.917	0.931 (0.247 - 3.742)			
Days in storage (linear)	0.545	0.483	0.958 (0.852 - 1.079)			
Donor Age	0.352	0.687	0.988 (0.936 - 1.044)			
Donor Sex (female)	0.797	0.599	0.820 (0.395 - 1.754)			
Donor-Recipient Sex Mismatch	0.568	0.338	1.395 (0.713 - 2.812)			
Days in storage (linear)	0.106	0.099	0.886 (0.764 - 1.019)			
Donor Age	0.256	0.237	0.962 (0.902 - 1.025)			
Donor Sex (female)	0.746	0.578	0.758 (0.282 - 2.015)			
Donor-Recipient Sex Mismatch	0.122	0.724	0.838 (0.307 - 2.216)			

\*Covariates were included if P < .15 on univariable analysis

- 12% (N = 44/360) failed
  - TKA or UKA: N = 22
  - > Revision cartilage: N = 22
- Mean time to fail: 3.8 ± 2.9 years
  0.6-12.8 years
- **No difference** in survivability free from **failure** on log-rank testing
- 5-year survivability
  - Sex match: 90.1%
  - Sex mismatch: 88.9%





- Variables associated with failure:
  - Diabetes mellitus
  - Higher number of previous surgeries
  - Longer symptom duration
- No donor variables associated with failure
  - Storage time ≥ 25 days trended toward significance (P = 0.065)

Cox Regression Analysis for Variables Associated with Failure					
Variable	P-value		Hazard Ratio		
	Univariable	Multivariable	(95% CI)		
Donor age	0.773	0.491	1.018 (0.967 - 1.071)		
Donor sex (female)	0.615	0.941	0.969 (0.425 - 2.211)		
Donor-recipient Sex Mismatch	0.569	0.752	1.106 (0.589 - 2.077)		
Days in storage (linear)	0.684	0.542	1.034 (0.927 - 1.153)		
Days in storage (binomial ≥ 25 days)	0.121	0.065	0.523 (0.263 – 1.043)		

\*Covariates were included if P < .15 on univariate

## Discussion



- Optimal donor variables and matching requirements remain debated
  - Merkely et al. found inferior cumulative 5-year survivorship among female patients who received an allograft from a male
  - Nuelle et al. found inferior visual analogue scale scores among patients who received grafts that had longer storage times
  - > Wang et al. did not appreciate PRO, reoperation, or failure differences in those with non-orthotopic OCA transplantation (e.g., medial to lateral condyle)
- Further study is needed to assess whether there are clinically-relevant immune responses in unmatched osteochondral allografts

AJSM, 2022

Association of Sex Mismatch Between Donor and Recipient With Graft Survivorship at 5 Years After Osteochondral Allograft Transplantation

Gergo Merkely <sup>1</sup>, Evan M Farina <sup>1</sup>, Chilan B G Leite <sup>1</sup> <sup>2</sup>, Jakob Ackermann <sup>3</sup>, Simon Görtz <sup>1</sup>, Christian Lattermann <sup>1</sup>, Andreas H Gomoll <sup>4</sup>

J Knee Surg, 2017

Patient Factors, Donor Age, and Graft Storage Duration Affect Osteochondral Allograft Outcomes in Knees with or without Comorbidities

Clayton W Nuelle <sup>1</sup>, Julia A V Nuelle <sup>1</sup>, James L Cook <sup>1</sup>, James P Stannard <sup>1</sup>

## Conclusions



- The primary finding from this investigation was that there is **no** substantial difference in terms of **clinically significant outcomes or failures** following OCA transplantation for patients who received a graft from a donor of the opposite sex.
- These data can help inform graft selection, expedient recipient selection, and outcome optimization following OCA transplantation.



# Thank you.





